What Iberogast Treats: Main Uses and Benefits

Iberogast is a herbal preparation used to manage symptoms associated with functional gastrointestinal disorders. It is primarily utilized for conditions where no structural cause for the symptoms is identified through routine clinical investigations.

Functional Dyspepsia

One of the primary uses of Iberogast is the management of functional dyspepsia, commonly referred to as indigestion. In this context, the preparation helps address a cluster of symptoms localized to the upper gastrointestinal tract, including:

• Upper Abdominal Pain: Easing discomfort or aching in the stomach area.
• Bloating and Gas: Reducing the sensation of fullness and abdominal pressure.
• Early Satiety: Managing the feeling of being full shortly after starting a meal.
• Heartburn: Alleviating the burning sensation in the chest or throat.
• Nausea: Reducing the feeling of sickness or stomach upset.

Irritable Bowel Syndrome (IBS)

Iberogast is also used to relieve symptoms of Irritable Bowel Syndrome, a condition affecting the lower digestive tract. It targets the varied manifestations of IBS, such as:

• Abdominal Cramping: Helping to relax the muscles in the digestive tract to reduce pain.
• Changes in Bowel Habits: Assisting in the management of constipation or diarrhea associated with IBS.
• Flatulence: Aiding in the reduction of intestinal gas production.

Therapeutic Benefits and Mechanism

The efficacy of Iberogast is attributed to its multi-target action on the gastrointestinal system. Rather than addressing a single symptom, it works across different parts of the digestive tract simultaneously. The main benefits include:

• Motility Regulation: It can help stimulate underactive stomach muscles while relaxing overactive ones, assisting in the normalization of peristalsis (the movement of food through the gut).
• Reduction of Hypersensitivity: It may help desensitize the nerves in the gut wall that transmit pain signals, which are often overactive in individuals with functional disorders.
• Anti-inflammatory Effects: Some components of the herbal blend possess properties that help soothe the lining of the digestive tract.
• Carminative Action: It assists in the breakdown and expulsion of gas, providing relief from pressure and bloating.

Regulatory References

1. Läkemedelsverket Public Assessment Report on Iberogast

Who Can and Cannot Use Iberogast?

The population eligibility for Iberogast is strictly defined by regulatory documents, focusing on age constraints, known allergies, and specific pre-existing health conditions.

Absolute Contraindications (Must Not Use)

Population Group	Restriction	Regulatory Basis
Children under 3 years	Use is prohibited (contraindicated)	Lack of sufficient clinical experience
Hypersensitivity	Known allergy to any component	Risk of allergic reaction

Conditional Use and Special Restrictions

Certain populations must use the medicine only after consulting a healthcare professional:

• Pre-existing Liver Disease: Patients must seek medical advice prior to use. This restriction is due to concerns related to hepatic safety and the medicine's composition.
• Alcoholism: Individuals with alcoholism must exercise caution, as the liquid solution contains approximately 31% v/v ethanol.
• Pregnancy and Lactation: Use is not recommended and should be avoided as a precaution. Medical consultation is required before use in these physiological states.
• Children 3 to 5 years: Use for abdominal pain requires medical consultation to rule out underlying serious conditions.
• Older Adults (Geriatric): Regulatory sources note that safety and efficacy data is not sufficiently established for this age group.

Interactions with other medicines and products

The official regulatory profile for Iberogast, a multi-component phytotherapeutic medicine, is defined by the absence of known drug interactions documented in current governmental labeling. This status applies to interactions with other prescribed medicines, over-the-counter products, herbal supplements, and substances such as food or alcohol.

Regulatory documents from health authorities, including those within Europe and Australia, consistently confirm that no specific, known interactions were identified during the product's assessment. This absence of documentation means that the official labeling does not contain formal restrictions or prohibitions related to co-administration based on interaction risk.

Regulatory Status of Interaction Categories

Interaction Category	Official Regulatory Status
Documented Drug–Drug Interactions	None documented.
Metabolic (PK) or Pharmacodynamic (PD) Effects	None documented.
Timing-Based Separation Rules	None documented.
Contraindicated Combinations	None documented.

The official labeling does not specify any substances that are contraindicated due to interaction risk. Furthermore, there are no mandatory requirements for separating the timing of Iberogast administration from other medicines or food intake, as no specific absorption, distribution, or clearance-altering effects have been officially documented. The overall interaction profile is officially characterized by a lack of known, clinically relevant interaction constraints.

The mechanism of action is defined by a multi-target approach engaging several distinct pharmacological domains, leading to an integrated effect on digestive physiology.

Biphasic Regulation of Smooth Muscle Tone

The extracts act as a balanced modulator of gastrointestinal movement, targeting both Ca^2+ channels and muscarinic M2 receptors ( M2 R) on smooth muscle. This dual-action mechanism enables the gut to relax spastic, overly-contracted segments (antispasmodic effect) while simultaneously stimulating tone and function in hypo-contracted areas (prokinetic effect), thereby modulating the rhythm of movement toward baseline tone.

Modulation of Visceral Afferent Signaling

The drug components modulate key receptors within the Enteric Nervous System (ENS), including Serotonin 5- HT3 and mu-Opioid receptors, located on sensory (afferent) nerve endings. By altering the signaling dynamics of these neurons, the mechanism reduces the sensitivity threshold to physical stimuli and chemical signals, influencing the signal transduction threshold for afferent input.

Influence on Mucosal Barrier Function and Epithelial Secretion

Select components influence the epithelial lining and secretory processes through mechanisms like A2 A receptor modulation and the activation of epithelial chloride channels. This action influences epithelial barrier characteristics and modulates low-grade inflammatory responses.

Iberogast oral drops, solution, must be administered orally and taken three times daily, before or with meals.

Official Dosing and Administration

To ensure correct administration of the oral drops, the bottle must be shaken well before each use. The required number of drops should be dispensed into a small amount of liquid, such as water or another beverage of choice, before being consumed.

The drops are typically counted by removing the white screw cap, inverting the bottle, holding it at a 45° angle, and giving a slight shake to release the drops one by one.

Age Group	Dose per Administration	Frequency
Adults and adolescents (from 13 years)	20 drops (1.0 mL)	3 times a day
Children 6 to 12 years	15 drops (0.75 mL)	3 times a day
Children 3 to 5 years	10 drops (0.5 mL)	3 times a day

Special Use Guidelines

• Pediatric Use: The product is not recommended for use in children under 3 years due to insufficient experience. For children under 6 years, a physician should be consulted if abdominal pain is present.
• Duration: The duration of use depends on the nature and course of the illness. If the patient's symptoms persist after the initial period of use, a doctor or pharmacist must be consulted.
• Missed Dose: If a dose is missed, patients should skip the missed dose and take the next scheduled dose when due. A double dose should not be taken to compensate for a missed one.
• Product Handling: Once the bottle has been opened, the oral solution should not be used for more than eight weeks.

Research Evidence / Overview of Studies for Iberogast

Evidence for Use in Functional Dyspepsia (FD)

Research into the use of this preparation for Functional Dyspepsia, a condition characterized by fluctuating or episodic manifestations in the upper digestive tract, includes Randomized Controlled Trials (RCTs). These short-term RCTs, often lasting between four and eight weeks, were conducted in adults and these studies sometimes used a placebo or an active comparator. Studies monitored patient-reported outcomes describing perceived discomfort, focusing on changes in overall symptom scores and individual symptoms such as epigastric pain, postprandial fullness, and early satiety.

Controlled studies and subsequent meta-analyses reported measurements of symptom score changes during the study period. Research highlights how symptoms evolved in the observed populations compared to the control groups, with reports documenting patterns in patient and investigator assessments of Global Efficacy. The structure of the research includes multiple controlled trials and systematic reviews, which some sources label as providing a high evidence level. However, long-term outcomes beyond the typical 4- to 8-week trial duration are not well characterized. Comparative evidence is lacking against many newer standard therapies.

Evidence for Use in Irritable Bowel Syndrome (IBS)

The research base for Irritable Bowel Syndrome (IBS), a condition associated with acute or disruptive episodes in the lower digestive tract, includes one key Randomized Controlled Trial and a variety of observational studies and real-world data collection. Research was studied for short-term symptom changes in adults diagnosed with IBS using established criteria. Studies monitored outcomes related to physical discomfort, specifically tracking measures of abdominal pain, cramping, and changes related to bowel function/disturbance.

However, the structure of the evidence for IBS is less robust than that for Functional Dyspepsia, and certainty remains low due to a limited number of core RCTs. Findings were mixed in some published analyses related to the observed patterns in bowel function/disturbance measures. The long-term effects are not fully established, as follow-up durations were limited in most of the core efficacy studies.

Key Studies & References

1. Public Assessment Report Scientific discussion Iberogast, oral drops solution (Läkemedelsverket/Swedish MPA)
2. Irritable bowel syndrome | Study 17063 (Efficacy/Safety study to confirm Iberogast's efficacy in patients with irritable bowel syndrome)
3. Functional Gastrointestinal Disorders | Study 20985 (Efficacy of Iberogast in patients with functional dyspepsia and concomitant reflux symptoms)

Common questions about Iberogast (FAQ)

Q: What is Iberogast?

A: Iberogast is an herbal medicinal product intended to relieve symptoms of functional gastrointestinal (GI) disorders. These disorders include functional dyspepsia (indigestion) and Irritable Bowel Syndrome (IBS). It is a liquid formulation for oral use.

---

Q: What is Iberogast used for?

A: Iberogast is traditionally used to treat various unpleasant symptoms associated with functional GI disorders, such as functional dyspepsia and IBS. These symptoms may include:

• Stomach pain and cramps
• Bloating
• Feeling of fullness
• Flatulence

---

Q: What are the main ingredients in Iberogast?

A: Iberogast is a combination of liquid extracts from nine different medicinal herbs. The specific herbal components include:

• Iberis amara (Bitter Candytuft)
• Angelica root
• Chamomile flower
• Caraway fruit
• St. Mary's Thistle fruit
• Lemon balm leaf
• Peppermint leaf
• Celandine herb
• Licorice root

These ingredients work together to help regulate the function of the stomach and intestines.

---

Q: How should I store Iberogast?

A: Iberogast should be stored at room temperature (below 25 C or 77 F) and kept out of sight and reach of children. The bottle should be tightly closed when not in use. Do not use the medicine after the expiry date which is stated on the carton and label.

---

Q: Are there any common side effects of Iberogast?

A: Like all medicines, Iberogast can cause side effects, although not everyone gets them. Hypersensitivity reactions (allergic reactions) are reported, but are rare (affecting up to 1 in 1,000 people). These can include:

• Skin rash
• Itching
• Shortness of breath
• Liver injury (in isolated, very rare cases)

If you experience any signs of an allergic reaction or symptoms suggestive of liver problems (e.g., yellowing of the skin or eyes, dark urine), you should stop using the product immediately and consult a healthcare professional.

---

Q: Can Iberogast be used during pregnancy or while breastfeeding?

A: As a precautionary measure, the use of Iberogast is not recommended during pregnancy or while breastfeeding. This is due to a lack of sufficient data on its safety in these specific groups. Always consult a healthcare professional before taking any medication during these periods.

Storage and Handling Requirements

The medicine must be stored at a temperature below 25, C and not refrigerated or frozen. Iberogast must be kept in its original outer carton to ensure it is protected from light, and the container should be kept tightly closed to maintain product integrity. The official labeling mandates that the product be kept out of the sight and reach of children.

---

Shelf-Life and Disposal

Once the bottle is opened for the first time, the solution has an in-use stability period of eight weeks; any remaining product should be discarded after this time. Do not dispose of unused or expired Iberogast by pouring it down the drain (wastewater) or placing it in household trash. To ensure proper environmental protection, consult a pharmacist regarding the correct method for returning or discarding the medicine.